natgillin/translations-raw huggingface dataset:
The DHPC and patient communication are aimed at increasing awareness about the fact that Humalog is now available in two strengths and describing key differences in the design of the packages and the prefilled pen devices to minimise the risk of medication errors and mix up between the two different strengths of Humalog.
Namen neposrednega obvestila zdravstvenim delavcem (DHPC) in informacij za bolnike je izboljšanje informiranosti o dejstvu, da je zdravilo Humalog zdaj na voljo v dveh jakostih in opis ključnih razlik v zasnovi pakiranj in napolnjenih peresnikov za zmanjšanje tveganj za napake pri zdravljenju in nenamerno zamenjavo dveh različnih jakosti zdravila Humalog.
The diagnosis must be confirmed by appropriate genetic testing.
Diagnoza mora biti potrjena z ustreznim genetskim testiranjem.
The diagnosis of ITP in adults and elderly patients should have been confirmed by excluding other clinical entities with thrombocytopenia.
Diagnoza ITP pri odraslih in starejših bolnikih mora biti potrjena z izključitvijo drugih kliničnih stanj, povezanih s trombocitopenijo.
The diagnosis of TMA should be considered in the occurrence of haemolytic anaemia, thrombocytopaenia, fatigue, fluctuating neurologic manifestation, renal impairment and fever.
Na TMA je treba pomisliti ob pojavu hemolitične anemije, trombocitopenije, utrujenosti, nihajočih nevroloških manifestacij, okvare ledvic in povišane telesne temperature.
The diagnostic approach should follow standard practice guidelines.
Diagnostiko PAH je treba izvesti v skladu z običajnimi smernicami.
The diagram below (see figure 1) shows what the ”SmartJect” pre-filled pen looks like.
Spodnji diagram (glejte sliko 1) prikazuje, kako izgleda napolnjeni injekcijski peresnik ”SmartJect”.
The diagram below shows the number of tablets to take every morning and every evening at each step, starting with step 5.
Spodnji diagram prikazuje število tablet, ki jih morate vzeti vsako jutro in vsak večer za vsak korak, začenši s korakom 5.
The diameter of the swelling is in general below 5 cm, but in some cases a larger size swelling may occur.
Premer otekline je večinoma manjši kot 5 cm, v nekaterih primerih pa je oteklina lahko večja.
The diarrhoea was managed (with the exception of euthanasia of one animal, 50 mg/kg/dose) with supportive care including intravenous fluid replacement therapy.
Diarejo so obvladali (razen pri eni živali, ki je prejela evtanazijo, odmerek 50 mg/kg) s podpornimi zdravili, vključno z intravenskim nadomeščanjem tekočine.
The diesters are lipophilic components ensuring an enhanced penetration into the skin associated to a low plasma availability.
Diestri so lipofilne komponente, ki zagotavljajo uspešnejšo penetracijo v kožo, povezano z nizko vsebnostjo v plazmi.
The difference between both vaccines in terms of percentage of subjects with OPA titres  8 was <5% for all serotypes in common, including 6B and 23F. Post-primary and post-booster OPA antibody geometric mean titres (GMTs) elicited by Synflorix were lower than those elicited by 7-valent Prevenar for the seven shared serotypes, except for serotype 19F.
Kar zadeva odstotek preiskovancev s titrom OPA  8, je bila razlika med cepivoma < 5 % za vse skupne serotipe, vključno s 6B in 23F. Postprimarna in poobnovitvena geometrijska sredina titrov (GMT- geometric mean titres) protiteles OPA, ki jih je proti sedmim skupnim serotipom izzvalo cepivo Synflorix, je bila – z izjemo serotipa 19F – nižja kot s 7-valentnim cepivom Prevenar.
The difference between imepitoin and phenobarbital groups in the seizure frequency per month after treatment (adjusted for baseline difference) was 0.004, 95% CI [-0.928, 0.935].
Razlika med skupinama z imepitoinom in fenobarbitalom v pogostnosti epileptičnih napadov na mesec po zdravljenju (prilagojena za razliko ob izhodišču) je bila 0,004, 95-odstotni IZ
The difference between imepitoin and phenobarbital groups in the seizure frequency per month after treatment (adjusted for baseline difference) was 0.004, 95% CI [-0.928, 0.935].
Razlika med skupinama z imepitoinom in fenobarbitalom v pogostnosti epileptičnih napadov na mesec po zdravljenju (prilagojena za razliko ob izhodišču) je bila 0,004, 95-odstotni IZ [- 0,928; 0,935].
The difference between Nordimet and Lantarel FS is that Nordimet is available in more strengths.
Razlika med zdravilom Nordimet in zdravilom Lantarel FS je, da je zdravilo Nordimet na voljo v več jakostih.
The difference between the change from baseline for Feraccru compared to placebo at week 12 was 2.25 g/dL (p<0.0001).
Razlika v spremembi od izhodišča do 12. tedna med zdravilom Feraccru in placebom je bila 2,25 g/dl (p < 0,0001).
The difference between the mean change from baseline to week 26/termination (LOCF, Last Observation Carried Forward) was statistically significant (UPDRS, parts I-III: for rasagiline 1 mg compared to placebo -4.2, 95% CI
Razlika med povprečno spremembo od izhodišča do 26 tedna/zaključka (Zadnje opazovanje preneseno vnaprej; Last Observation Carried Forward - LOCF) je bila statistično pomembna (UPDRS, deli I-III: za razagilin 1 mg v primerjavi s placebom -4,2, 95 % CI [-5,7, -2,7]; p
The difference between the mean change from baseline to week 26/termination (LOCF, Last Observation Carried Forward) was statistically significant (UPDRS, parts I-III: for rasagiline 1 mg compared to placebo -4.2, 95% CI
Razlika med povprečno spremembo od izhodišča do 26 tedna/zaključka (Zadnje opazovanje preneseno vnaprej; Last Observation Carried Forward - LOCF) je bila statistično pomembna (UPDRS, deli I-III: za razagilin 1 mg v primerjavi s placebom -4,2, 95% CI [-5,7, -2,7]; p < 0,0001; za razagilin 2 mg v primerjavi s placebom -3,6, 95% CI [-5,0, -2,1]; p < 0,0001; UPDRS
The difference between the treatment groups with respect to overall survival showed a significant clinical difference (p=0.029, log-rank test stratified by centre): survival rates at 53 months were 80.9% for patients in the R-CVP group compared to 71.1 % for patients in the CVP group
Razlika med terapevtskima skupinama glede celokupnega preživetja je pokazala značilno klinično razliko (p = 0,029, log-rang test s stratifikacijo po centru): po 53 mesecih je bil delež preživetja v skupini z R-CVP 80,9 % in v skupini s CVP 71,1 %.
The difference continued to be statistically significant through Month 6 in each study (p≤0.024).
Razlika je bila še naprej v obeh študijah statistično pomembna do 6. meseca (p ≤0,024).
The difference in antiplatelet activity between some COX-1 inhibiting NSAIDs and COX-2 selective inhibitors may be of clinical significance in patients at risk of thrombo-embolic reactions.
Razlika v antitrombocitni aktivnosti med nekaterimi nesteroidnimi protivnetnimi zdravili, ki zavirajo COX-1, in selektivnimi zaviralci COX-2 bi lahko bila klinično pomembna pri bolnikih, ki jih ogrožajo trombembolične reakcije.
The difference in AUC and Cmax of oxybutynin and the active metabolite N-desethyloxybutynin following transdermal administration of Kentera on either the abdomen, buttocks or hip is not clinically relevant.
Razlika med AUC in Cmax oksibutinina in aktivnega metabolita N- dezetiloksibutinina po nanosu transdermalnega obliža Kentera na trebuh, zadnjico ali boke ni klinično relevantna
The difference in bioavailability was less marked upon steady-state administration to renal transplant recipients, and therapeutic equivalence has been demonstrated in a randomised study of 477 patients.
Razlika v biološki uporabnosti je manj izrazita pri bolnikih s presajeno ledvico v stanju dinamičnega ravnovesja, terapevtsko ekvivalentnost pa so ugotovili v randomizirani študiji pri 477 bolnikih.
The difference in clearance between Fabry patients ≥ 65 years and those < 65 years was 20%, which was not considered clinically significant.
Razlika v očistku pri bolnikih s Fabryjevo boleznijo, starih 65 let ali več, in mlajših od 65 let, je znašala 20 %, kar ni klinično pomembno.
The difference in DRR between Imlygic and GM-CSF in the ITT population was statistically significant (see Table 4) in favour of Imlygic.
Razlika v DRR med zdravilom Imlygic in GM-CSF v populaciji z-namenom-zdravljenja je bila statistično značilna (glejte preglednico 4) v korist zdravila Imlygic.
The difference in mean body weight change between the 20 mg and placebo groups was 3.8 kg (CI95% -5.0, -2.6 p< 0.001).
Razlika v povprečni spremembi telesne mase med prejemniki 20 mg rimonabanta in prejemniki placeba je bila 3,8 kg (IZ95 % –5,0, –2,6, p < 0,001).
The difference in mean body weight change between the 20 mg and placebo groups was 3.8 kg (CI95% -5.0, -2.6 p<0.001).
Razlika v povprečni spremembi telesne mase med prejemniki 20 mg rimonabanta in prejemniki placeba je bila 3,8 kg (IZ95 % –5,0, –2,6, p < 0,001).
The difference in occurrence of pain was 9.9% (95% confidence interval 4-15.8%) between the Velactis treated cows compared to placebo treated animals.
Razlika v pojavu bolečine je bila 9.9% (95% intreval zaupanja 4.0-15.8%) med kravami zdravljenimi z zdravilom Velactis in kravami, ki so prejele placebo.
The difference in ORR per independent central review was 18% (CI: 0.6%, 35.3%) between the two treatment arms in the few patients who had evaluable tumor at baseline and had a confirmed response prior to receiving any local therapy : 27/75 patients (36.0%, 95% CI: 25.2%, 47.9%) in the Chemo arm and 34/63 patients (54.0%, 95% CI: 40.9%, 66.6%) in the Bv  Chemo arm.
Po neodvisnem centralnem pregledu je bila razlika v deležu celokupnega odziva med redkimi bolniki iz obeh zdravljenih skupin, ki so imeli ocenljiv tumor v izhodišču in potrjen odziv pred prejemom katerega koli lokalnega zdravljenja, 18 % (interval zaupanja: 0,6 %; 35,3 %): 27/75 bolnikov (36,0 %; 95-% interval zaupanja: 25,2 %; 47,9 %) iz skupine, ki je prejemala kemoterapijo, in 34/63 bolnikov (54,0 %; 95-% interval zaupanja: 40,9 %; 66,6 %) iz skupine, ki je prejemala kombinacijo bevacizumaba in kemoterapije.
The difference in overall survival (OS) was statistically in favour of sunitinib [hazard ratio: 0.491 (95%CI: 0.290 - 0.831)]; the risk of death was 2 times higher in patients in the placebo arm compared to the sunitinib arm.
Razlika v celokupnem preživetju je bila statistično v prid sunitinibu [razmerje ogroženosti: 0,491; 95 % IZ: 0,290-0,831]; tveganje za smrt je bilo v skupini s placebom 2-krat večje kot v skupini s sunitinibom.
The difference in percentage of new intramammary infections during the dry period between Velactis treated animals and the placebo group was 5.5% (95% confidence interval 0.5-10.4%).
Razlika v odstotku novih intramamarnih okužb v obdobju presušitve med živalmi zdravljenimi z zdravilom Velactis in s placebom je bila 5.5% (95% intreval zaupanja 0.5- 10.4%).
The difference in response rates between the two studies was due to differences in the types of patients and infections being treated.
Razlike v stopnjah odziva med obema študijama so nastale zaradi vrste bolnikov in okužb, ki so jih zdravili v posameznih študijah.
The difference in the HBeAg seroconversion rates (HBeAg and HBV DNA loss with HBeAb detection) between placebo and lamivudine was not statistically significant in this population (rates after one year were 13 % (12/95) for placebo versus 22 % (42/191) for lamivudine; p=0.057).
Pri tej populaciji razlika v odstotkih serokonverzije HBeAg (izginotje HBeAg in HBV DNA ter pojav protiteles HBeAb) med placebom in lamivudinom ni bila statistično pomembna (po enem letu je bila 13 % (12/95) za placebo v primerjavi z 22 % (42/191) za lamivudin; p = 0,0057).
The difference in the HBeAg seroconversion rates (HBeAg and HBV DNA loss with HBeAb detection) between placebo and lamivudine was not statistically significant in this population (rates after one year were 13 % (12/95) for placebo versus 22 % (42/191) for lamivudine; p=0.057).
Pri tej populaciji razlika v odstotkih serokonverzije HBeAg (izginotje HBeAg in HBV DNA, ter pojav protiteles HBeAb) med placebom in lamivudinom ni bila statistično signifikantna (po enem letu je bila 13 % (12/95) za placebo v primerjavi z 22 % (42/191) za lamivudin; p = 0,0057).
The difference in the overall SVR12 rates between sofosbuvir + ribavirin and peginterferon alfa + ribavirin treatment groups was 0.3% (95% confidence interval: -7.5% to 8.0%) and the study met the predefined non-inferiority criterion.
Razlika v stopnjah celokupnega SVR12 med skupinami, zdravljenimi s sofosbuvirjem + ribavirinom in peginterferonom alfa + ribavirinom, je bila 0,3 % (95-odstotni interval zaupanja: -7,5 % do 8,0 %), študija pa je izpolnjevala vnaprej določene kriterije neinferiornosti.
The difference in the proportion of patients who maintained < 400 copies/ml at week 48 was mainly influenced by the higher number of discontinuations in the tenofovir disoproxil fumarate treatment group.
Na razliko v deležu bolnikov, ki so ohranili < 400 kopij/ml v 48. tednu, je v glavnem vplivalo večje število prekinitev v skupini zdravljenja z dizoproksiltenofovirijevim fumaratom.
The difference is for Tresiba Flex – Tresiba
To je razlika med Tresiba Flex – Tresiba.
The difference is unlikely to be of clinical relevance, though.
Razlika verjetno ni klinično pomembna.
The difference of response rate at Week 48 is 1% (95% confidence interval -3% to 6%) using normal approximation.
Razlika stopnje odziva v 48. tednu je 1 % (95-odstotni interval zaupanja -3 % do 6 %) z normalnim približanjem.
The difference of response rate is 1% (95% confidence interval -3% to 6%) using normal approximation.
Razlika stopnje odziva je 1 % (95-odstotni interval zaupanja -3 % do 6 %) z normalnim približanjem.
The difference percentage of new intramammary infections during the dry period between Velactis treated animals and the placebo group was 5.5% (95% confidence interval 0.5-10.4%).
Razlika v odstotku novih intramamarnih okužb v obdobju presušitve med živalmi zdravljenimi z zdravilom Velactis in s placebom je bila 5.5% (95% intreval zaupanja 0.5- 10.4%).
The difference versus ezetimibe was statistically significant at week 24 for LDL-C, Total-C, Non-HDL-C and Apo B.
Razlika v primerjavi z ezetimibom je bila 24. teden statistično značilna za LDL-H, celokupni holesterol, ne-HDL in Apo B.
The difference was driven by the outcome in the group of patients with ≥ 5 % weight loss after 12 weeks of treatment with orlistat representing 19 % of the initial population.
Na razliko je močno vplival rezultat skupine bolnikov z  5-% izgubo telesne mase po 12 tednih zdravljenja z orlistatom, ki so predstavljali 19 % prvotne populacije.
The difference was maintained from Day 7 through Month 6 (Figure 1).
Razlika se je ohranila od 7. dne do 6. meseca (slika 1).
The difference was statistically significant (Difference -13.3% CI95% -16.5; -10.2% p< 0.001).
Razlika je bila statistično značilna (razlika – 13,3 %, IZ95 % –16,5 %, –10,2 %; p<0,001).
The difference was statistically significant (Difference -13.3% CI95% -16.5; -10.2% p<0.001).
Razlika je bila statistično značilna (razlika – 13,3 %, IZ95 % –16,5 %, –10,2 %; p<0,001).
The differences are considered of no clinical relevance since Xultophy is initiated and titrated according to the individual patient’s blood glucose targets.
Te razlike ne veljajo za klinično pomembne, saj se zdravilo Xultophy uvede in titrira v skladu s ciljnimi koncentracijami glukoze v krvi pri vsakem posameznem bolniku.
The differences between the two groups, 125 mg twice daily and 250 mg twice daily, were not statistically significant but there was a trend towards improved exercise capacity in the group treated with 250 mg twice daily.
Razlike med skupinama z odmerkom 125 mg dvakrat na dan in 250 mg dvakrat na dan niso bile statistično značilne, čeprav je bil prisoten trend izboljšanja fizične zmogljivosti v skupini, ki je jemala odmerek 250 mg dvakrat na dan.
The differences between the two nivolumab- containing groups were evaluated descriptively.
Razlike med dvema skupinama z nivolumabom so bile ocenjene opisno.
The digital display will show the number of doses that have been delivered.
Digitalni prikazovalnik bo prikazal število dovedenih odmerkov.
The diluent contains polysorbate 80 (E 433), macrogol 400 and anhydrous ethanol.
Vehikel vsebuje polisorbat 80 (E433), makrogol 400 in brezvodni etanol.
The diluent contains: polysorbate 80 (E 433), macrogol 400 and anhydrous ethanol.
Vehikel vsebuje: polisorbat 80 (E433), makrogol 400 in brezvodni etanol.
The diluent is a clear to slightly turbid, light-yellow to yellow solution, free from visible particulates.
Vehikel je bistra do rahlo motna, svetlo rumena do rumena raztopina, brez vidnih delcev.
The diluent is a clear to slightly turbid, light-yellow to yellow solution.
Vehikel je bistra do rahlo motna, svetlo rumena do rumena raztopina.
The diluent is clear and colourless.
Vehikel je bister in brezbarven.
The diluted concentrate is chemically and physically stable for 3 days at 2°C to 8°C and at room temperature (up to 25°C).
Razredčeni koncentrat je kemijsko in fizikalno stabilen 3 dni pri 2 °C do 8 °C ter pri sobni temperaturi (do 25°C) .
The diluted medicinal product is to be used as soon as possible and within 8 hours of dilution.
Raztopino uporabite takoj, ko je mogoče in najpozneje 8 ur po razredčitvi.
The diluted medicinal product should then be administered as a 20 – 50-minute intravenous infusion through a sterile, non-pyrogenic infusion, single-use, low protein binding filter (0.2 µm).
Razredčeno zdravilo je treba potem dati v obliki 20- do 50-minutne intravenske infuzije preko sterilnega, apirogenega filtra z majhno vezavo beljakovin (0,2 µm), za enkratno uporabo.
The diluted solution can be held for up to 24 hours at 2C – 8C.
Razredčeno raztopino lahko shranjujete do 24 ur pri temperaturi 2 °C - 8 °C.
The diluted solution for infusion can be stored at ambient temperature (15°C to 25°C)for up to 6 hours or in the refrigerator (2ºC - 8ºC) for no more than 24 hours prior to use.
Razredčeno raztopino za infundiranje lahko hranite pri sobni temperaturi (15 – 25 °C) do 6 ur ali v hladilniku (2 – 8 ºC) do 24 ur pred uporabo.
The diluted solution for infusion can be stored in the refrigerator (2°C - 8°C) for no more than 24 hours prior to use.
Razredčeno raztopino za infundiranje lahko pred uporabo do 24 ur hranite v hladilniku (2 – 8 °C).
The diluted solution for infusion must have a final concentration of 1 to 5 mg/ml dalbavancin (see section 6.6).
Razredčena raztopina za infundiranje mora imeti končno koncentracijo od 1 do 5 mg/ml dalbavancina (glejte poglavje 6.6).
The diluted solution is administered to patients using an infusion set.
Razredčena raztopina se daje bolnikom z infuzijskim kompletom.
The diluted solution is to be used within 6 hours after dilution.
Razredčeno raztopino porabite v 6 urah po redčenju.
The diluted solution is to be visually inspected for particulate matter prior to use.
Pred uporabo se je treba prepričati, da razredčena raztopina ne vsebuje vidnih delcev.
The diluted solution may be stored for up to 24 hours in a refrigerator (2°C – 8°C).
Razredčeno raztopino lahko shranjujete v hladilniku (2 °C - 8 °C) do skupno 24 ur.
The diluted solution must be mixed thoroughly by inverting several times.
Vrečko morate temeljito premešati z nekajkratnim obračanjem .
The diluted solution must be mixed thoroughly by inverting several times.
Vrečko z razredčeno raztopino morate temeljito premešati z nekajkratnim obračanjem.
The diluted solution must be used within 8 hours.
Razredčeno raztopino porabite v 8 urah.
The diluted solution must not be heated in a microwave or with any heat source other than the prevailing room temperature.
Razredčene raztopine ne smete segrevati v mikrovalovni pečici ali z drugim virom toplote, ogreti se sme samo s toploto zraka pri temperaturi okolice.
The diluted solution of Soliris should be administered by intravenous infusion over 25 to
Razredčena raztopina zdravila Soliris se daje v obliki intravenske infuzije, ki naj traja 25 do
The diluted solution of Soliris should be administered by intravenous infusion over 25 – 45 minutes in adults and 1-4 hours in paediatric patients via gravity feed, a syringe-type pump, or an infusion pump.
Razredčena raztopina zdravila Soliris se daje v obliki 25 – 45-minutne intravenske infuzije pri odraslih oziroma 1 – 4-urne intravenske infuzije pri pediatričnih bolnikih s pomočjo kapalnega sistema, brizgalne črpalke ali infuzijske črpalke.
The diluted solution should be administered to patients using a low-protein binding infusion set equipped with an in-line, low-protein binding 0.2 μm filter, with a surface area of greater than 4.5 cm2 as available in order to avoid filter occlusion.
Razredčeno raztopino je treba bolniku dati z infuzijskim kompletom z majhno vezavo beljakovin, opremljenim z vgrajenim filtrom velikosti 0,2 μm z majhno vezavo beljakovin, s površino večjo kot 4,5 cm2, ki je na voljo, da se prepreči zamašitev filtra.
The diluted solution should be allowed to warm to room temperature [18°C – 25°C] prior to administration by exposure to ambient air.
Pred uporabo razredčeno raztopino izpostavite temperaturi v okolici in počakajte, da se ogreje na sobno temperaturo [18 °C – 25 °C].
The diluted solution should be inspected visually for particulate matter and discolouration prior to administration.
Razredčeno raztopino je treba pred uporabo pregledati in se prepričati, da ne vsebuje delcev in da ni obarvana.
The diluted solution should be protected from light until administration (see section 6.3).
Razredčeno raztopino morate zavarovati pred svetlobo vse do dajanja.
The diluted solution should be use immediately
Redčeno raztopino je treba nemudoma uporabiti.
The diluted sterile concentrate is chemically and physically stable for 12 hours at or below 25°C.
Razredčeni sterilni koncentrat je kemično in fizikalno stabilen 12 ur pri temperaturi do vključno 25 °C.
The diluted vaccine prepared as described is mixed by gentle agitation so as to be ready for use.
Razredčeno cepivo pripravljeno kot je opisano nežno mešajte z rahlim stresanjem dokler ni pripravljeno za uporabo.
The diluted vaccine prepared as described is mixed by gentle agitation so as to be ready for use.
Razredčeno cepivo, ki je pripravljeno, kot je bilo opisano, zmešajte z rahlim pretresanjem in že je pripravljeno za uporabo.
The diluted vaccine prepared as described is mixed by gentle agitation.
Razredčeno cepivo pripravljeno kot je opisano nežno mešajte z rahlim stresanjem.
The diluted Zoledronic Acid Hospira infusion solution should be used immediately in order to avoid microbial contamination.
Razredčeno raztopino za infundiranje Zoledronska kislina Hospira je treba uporabiti takoj, da se prepreči mikrobna kontaminacija.
The diluted Zometa infusion solution should be used immediately in order to avoid microbial contamination.
Razredčeno infuzijsko raztopino zdravila Zometa morate porabiti takoj, da bi preprečili onesnaženje z mikroorganizmi.
The diluted Zometa infusion solution should be used immediately in order to avoid microbial contamination.
Razredčeno raztopino za infundiranje zdravila Zometa, morate porabiti takoj, da bi preprečili onesnaženje z mikroorganizmi.
The dilution is to be made under aseptic conditions.
Redčenje je treba opraviti v aseptičnih razmerah.
The diphtheria and tetanus toxoids are prepared from the toxins of cultures of Corynebacterium diphtheriae and Clostridium tetani by formaldehyde detoxification followed by purification.
Clostridium tetani s prečiščevanjem in razstrupljanjem s formaldehidom.
The diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliomyelitis (DTPa-HBV- IPV) component is a white, slightly milky liquid presented in a glass vial (0.5 ml).
Komponenta cepiva (DTPa-HBV-IPV) davica, tetanus, pertusis (acelularni), hepatitis B, poliomielitis (inaktivirani) je bela, rahlo mlečna tekočina v stekleni viali (0,5 ml).
The diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliomyelitis (DTPa-HBV- IPV) component is a white, slightly milky liquid presented in a pre-filled syringe (0.5 ml).
Komponenta cepiva (DTPa-HBV-IPV) davica, tetanus, pertusis (acelularni), hepatitis B, poliomielitis (inaktivirani) je bela, rahlo mlečna tekočina v napolnjeni injekcijski brizgi (0,5 ml).